News

FOLFOXIRI Plus Bevacizumab Reinstated Post-Progression Preferable Strategy for mCRC

04/06/2020

Upfront FOLFOXIRI plus bevacizumab reintroduced after progression is preferable to chemotherapy doublets for metastatic CRC, according to results from the TRIBE2 study.

Upfront FOLFOXIRI plus...

04/06/2020

Oncology

News

Disease Progression Tied to Reduced QoL in Adults With Cancer

03/27/2020

A link exists between disease progression and reduced QoL in patients with metastatic breast, pancreatic, lung, and colorectal cancers.

A link exists between disease...

03/27/2020

Oncology

News

Acupuncture Significantly Reduces Chemo-Induced Peripheral Neuropathy

03/24/2020

In patients with solid tumors, acupuncture significantly improved symptoms of chemo-induced peripheral neuropathy compared with usual care.

In patients with solid tumors,...

03/24/2020

Oncology

News

Tumor Deposits an Independent Prognosticator of DFS in Stage III Colon Cancer

03/18/2020

Findings from a post hoc analysis of the IDEA France trial suggest that tumor deposits are an independent prognostic factor for DFS in stage III colon cancer.

Findings from a post hoc...

03/18/2020

Oncology

News

Adding Bevacizumab to TAS-102 Potentially Practice-Changing for Metastatic CRC

03/02/2020

TAS-102 plus bevacizumab yields clinically significant PFS improvement over TAS-102 monotherapy in patients with metastatic CRC, according to findings from a phase 2 study.

TAS-102 plus bevacizumab yields...

03/02/2020

Oncology

News

Experts Establish Optimal Durations of CAPOX and FOLFOX for High-Risk CRC

03/02/2020

Treatment durations of 3 months and 6 months for CAPOX or FOLFOX therapy, respectively, are optimal for patients with high-risk, stage II CRC, according to the TOSCA trial.

Treatment durations of 3 months...

03/02/2020

Oncology

News

Cetuximab Decreases OS in Patients With Resectable Colorectal Liver Metastasis

02/20/2020

A long-term analysis of the New EPOC study led investigators to assert that cetuximab therapy should not be used in patients with resectable colorectal liver metastasis.

A long-term analysis of the New...

02/20/2020

Oncology

News

Long-Term Locoregional Treatment Benefits Observed in Patients With Oligometastatic CRC

02/07/2020

Study findings suggest that oligometastatic CRC is a positive prognostic factor tied to a higher magnitude of long-term benefit from locoregional treatments.

Study findings suggest that...

02/07/2020

Oncology

News

CAPOX With Intermittent Oxaliplatin Promising Treatment for Colon Cancer

02/05/2020

Phase 2 trial findings suggest that combining CAPOX with intermittent oxaliplatin could be as effective as adjuvant chemo after curative resection for stage II/III colon cancer.

Phase 2 trial findings suggest...

02/05/2020

Oncology

News

Pros and Cons of Decompressing Stoma Presurgery for Left-Sided Obstructive CRC

01/31/2020

Decompressing stoma has advantages and disadvantages as bridge to resection of left-sided obstructive colon cancer.

Decompressing stoma has...

01/31/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology